Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.
-
O'Brien CR, Li M, Morton C. An 80-Year-Old Man With a 24-Hour History of Epigastric Pain. Chest. 2019 12; 156(6):e127-e131.
-
Rajapreyar I, Samson R, Ennezat PV, Jemtel THL. Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy. J Card Fail. 2019 Aug; 25(8):686-689.
-
Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines. Headache. 2017 Oct; 57(9):1375-1384.
-
Dong YH, Alcusky M, Maio V, Liu J, Liu M, Wu LC, Chang CH, Lai MS, Gagne JJ. Evidence of potential bias in a comparison of ß blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. BMJ Open. 2017 03 31; 7(3):e012997.
-
Mysliwiec M, Bonita RE. Outpatient Emergencies: Acute Heart Failure. Med Clin North Am. 2017 May; 101(3):507-519.
-
Schmidt JM, Crimmins M, Lantigua H, Fernandez A, Zammit C, Falo C, Agarwal S, Claassen J, Mayer SA. Prolonged elevated heart rate is a risk factor for adverse cardiac events and poor outcome after subarachnoid hemorrhage. Neurocrit Care. 2014 Jun; 20(3):390-8.
-
Irani F, Herial N, Colyer WR. Impact of an acute coronary syndrome pathway in achieving target heart rate and utilization of evidence-based doses of beta-blockers. Am J Ther. 2012 Nov; 19(6):397-402.
-
Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, Piña IL, Whellan D, O'Connor CM. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol. 2012 Jul 17; 60(3):208-15.
-
Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W, Wilde AA, McNitt S, Peterson DR, Zareba W, Robinson JL, Ackerman MJ, Cypress M, Gray DA, Hofman N, Kanters JK, Kaufman ES, Platonov PG, Qi M, Towbin JA, Vincent GM, Lopes CM. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to ß-blocker therapy in type 1 long-QT syndrome. Circulation. 2012 Apr 24; 125(16):1988-96.
-
Goldenberg I, Thottathil P, Lopes CM, Moss AJ, McNitt S, O-Uchi J, Robinson JL, Zareba W, Ackerman MJ, Kaufman ES, Towbin JA, Vincent M, Barsheshet A. Trigger-specific ion-channel mechanisms, risk factors, and response to therapy in type 1 long QT syndrome. Heart Rhythm. 2012 Jan; 9(1):49-56.